BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31099202)

  • 1. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
    Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Na YM; Cho JS; Park MH
    Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
    Dou Y; Chen Y; Hu D; Su X
    Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
    Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
    Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
    Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
    Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine.
    Matrone A; Faranda A; Latrofa F; Gambale C; Stefani Donati D; Molinaro E; Agate L; Viola D; Piaggi P; Torregrossa L; Basolo F; Elisei R
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32453405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.
    Schumm MA; Lechner MG; Shu ML; Ochoa JE; Kim J; Tseng CH; Leung AM; Yeh MW
    Endocr Pract; 2021 Jul; 27(7):691-697. PubMed ID: 33642257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of thyroid hormone supplementation after thyroid lobectomy.
    Lee DY; Seok J; Jeong WJ; Ahn SH
    J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.
    Park JH; Lee YM; Lee YH; Hong SJ; Yoon JH
    J Surg Oncol; 2018 Sep; 118(3):390-396. PubMed ID: 30114333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer.
    Lee JC; Song BS; Kang YM; Kim YR; Kang YE; Lee JH; Shong M; Yi HS
    Front Endocrinol (Lausanne); 2021; 12():769074. PubMed ID: 34858341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.
    Ito M; Miyauchi A; Morita S; Kudo T; Nishihara E; Kihara M; Takamura Y; Ito Y; Kobayashi K; Miya A; Kubota S; Amino N
    Eur J Endocrinol; 2012 Sep; 167(3):373-8. PubMed ID: 22711760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma.
    Ahn D; Lee GJ; Sohn JH; Jeon JH
    Head Neck; 2020 May; 42(5):1004-1013. PubMed ID: 31930773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
    Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.